After two years of aggressive shareholder activism, Carl Icahn and other shareholders of Biogen Idec will meet today at the company’s annual general meeting to consider the new slate of directors posed by the infamous activist. According to Forbes, today’s meeting will be the second in which Icahn has attempted a reshuffling at the biotech.
Icahn, whose Icahn Associates fund owns a 5.6 percent Biogen stake, has crusaded against the company’s management, alleging that current directors have sabotaged attempts to sell the company. Icahn’s current line is that the company should split itself into two separate units.
Icahn has presented four potential nominees for the 12-person Biogen board. Two of the nominees were part of his failed attempt at a board sweep last year.